The key agents involved in spreading Parkinson's Disease in the brain were thought to be too unstable to study in depth, but in new research scientists have both characterized these toxic structures, and established how they 'drill' into the walls of healthy brain cells.
High-intensity exercise three times a week is safe for individuals with early-stage Parkinson's disease and decreases worsening of the disease's symptoms, according to results of a study published in the Dec. 11 issue of JAMA Neurology.
Researchers at Cardiff University, in collaboration with the University of Dundee, have identified a drug molecule within a medicine used to treat tapeworm infections which could lead to new treatments for patients with Parkinson's disease.
High-intensity exercise three times a week is safe for individuals with early-stage Parkinson's disease and decreases worsening of motor symptoms, according to a new phase 2, multi-site trial led by University of Colorado Anschutz Medical Campus and Northwestern Medicine scientists.
Researchers have developed new single-cell sequencing methods that could be used to map the cell origins of various brain disorders, including Alzheimer's, Parkinson's, schizophrenia and bipolar disorder. By analyzing individual nuclei of cells from adult human brains, researchers have identified 35 different subtypes of neurons and glial cells and discovered which of these subtypes are most susceptible to common risk factors for different brain diseases.
High-intensity exercise three times a week is safe for individuals with early-stage Parkinson's disease and delays progression of motor symptoms, reports a new study of individuals with the disease. The exercise needs to between 80 and 85 percent maximum heart rate for the benefit. It's the first time high-intensity exercise has been tested in Parkinson's patients. It was previously thought it was too physically stressful for patients.
A drug already used to treat certain forms of cancer appears to be an effective therapy for Huntington's disease, and offers a potential pathway to treat other neurodegenerative diseases.
Researchers from Aarhus University have discovered that patients with the RBD sleep behavior disorder lack dopamine and have a form of inflammation of the brain. This means that they are at risk of developing Parkinson's disease or dementia when they grow older.
A new small-molecule drug can restore brain function and memory in a mouse model of Alzheimer's disease. The molecule, called anle138b, works by stopping toxic ion flow in the brain that is known to trigger nerve cell death. Scientists envision that this drug could be used to treat Alzheimer's and other neurodegenerative diseases such as Parkinson's and ALS.
Female Parkinson's disease patients are much less likely than male patients to have caregivers, despite the fact that caregivers report greater strain in caring for male patients. The findings come from a large study reported today in Neurology by researchers at the Perelman School of Medicine at the University of Pennsylvania. According to the researchers, the disparity between female and male patients probably derives in part from the fact that women tend to outlive their most likely potential caregivers: their husbands.